Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The enzyme encoded by GLO1 is responsible for the catalysis and formation of S-lactoyl-glutathione from methylglyoxal condensation and reduced glutatione. Additionally we are shipping Glyoxalase I Proteins (24) and Glyoxalase I Kits (23) and many more products for this protein.
Showing 10 out of 103 products:
Human Monoclonal GLO1 Primary Antibody for ELISA, ICC - ABIN449661
Mailankot, Padmanabha, Pasupuleti, Major, Howell, Nagaraj: Glyoxalase I activity and immunoreactivity in the aging human lens. in Biogerontology 2011
Show all 2 references for ABIN449661
Human Polyclonal GLO1 Primary Antibody for ELISA, WB - ABIN561054
Sato, Kwon, Kamisuki, Srivastava, Mao, Kawazoe, Uesugi: Polyproline-rod approach to isolating protein targets of bioactive small molecules: isolation of a new target of indomethacin. in Journal of the American Chemical Society 2007
Show all 2 references for ABIN561054
Human Polyclonal GLO1 Primary Antibody for EIA, WB - ABIN453056
Germanová, Germanová, Tesarová, Jáchymová, Zvára, Zima, Kalousová: Glyoxalase I Glu111Ala polymorphism in patients with breast cancer. in Cancer investigation 2009
Show all 2 references for ABIN453056
Human Polyclonal GLO1 Primary Antibody for ICC, IF - ABIN441467
Gabriele, Lombardi, Sacco, Napolioni, Altieri, Tirindelli, Gregorj, Bravaccio, Rousseau, Persico: The GLO1 C332 (Ala111) allele confers autism vulnerability: family-based genetic association and functional correlates. in Journal of psychiatric research 2014
Alternative detoxification of methylglyoxal in GLO1(-/-) is achieved by increased catalytic efficiency of aldose reductase (show AKR1B1 Antibodies) toward hemithioacetal (product of glutathione and methylglyoxal ), which is most likely caused by S-nitrosylation of aldose reductase (show AKR1B1 Antibodies).
Glo1 knockdown does not have major short term effects on the energy expenditure or the formation of atherosclerotic plaques.
Crystal structure of the mouse Glo1-inhibitor complex was determined at 2.3 A resolution.
Study demonstrates that GLO1 is a novel metabolic oncogene (show RAB1A Antibodies) of the 6p21 amplicon, which promotes tumor growth and aberrant transcriptional signals via regulating cellular metabolic activities for energy production.
the balance between methylglyoxal and age-dependent GLO1 downregulation contributes to delayed wound healing in old mice
The difference in glyoxalase-1 mRNA was observed with Fkbp5 (show FKBP5 Antibodies)-/- mice expressing 2-fold more glyoxylase-1 protein.
pharmacological inhibition of GLO1 reduced anxiety, suggesting that GLO1 is a possible target for the treatment of anxiety disorders.
These results suggest that GLO-1 plays a role in high glucose-mediated signaling by reducing mesangial cells accumulation and oxidative stress in diabetes mellitus.
Findings reveal that the abundance of GLO1 varies between different murine strains and within different sensory neuron populations.
Data show that reducing RGS2 (show RGS2 Antibodies) expression by antisense treatment prevented the increase in GLO1 and GSR1 (show GSR Antibodies) mRNA and protein expression.
Reduction of GLO1 activity in atherosclerotic lesions of nondiabetic patients with increased HbA1c is associated with a functional involvement of this protective enzyme in atherogenesis.
Studies suggest that the enhancement of glyoxalase I (GLO-1) is a promising strategy aimed at halting the vicious cycle between chronic kidney disease and increases in glycative stress.
GLO1 on one hand is crucial to maintaining tumor characteristics of malignant cells, and, on the other hand, supports malignant transformation of cells in a hypoxic environment when overexpressed.
GLO1 SNPs are significantly associated with late-onset and drug-resistant epilepsy.
MS5 (show TNFRSF1A Antibodies) induced hydrogen peroxide-mediated c-Jun (show JUN Antibodies)-dependent Glo1 up-regulation which resulted in a decrease in the Argpyrimidine-modified Hsp70 (show HSP70 Antibodies) protein level which triggered EMT (show ITK Antibodies) in a novel mechanism involving miR (show MLXIP Antibodies)-21 and SMAD (show SMAD1 Antibodies) signalling
MMP-9 (show MMP9 Antibodies) and Bcl-2 (show BCL2 Antibodies) expression levels were dramatically decreased by addition of methylglyoxal or inhibition of GLOI. These findings may provide a new approach for the treatment of breast cancer.
Data suggest Glo1's effects on anxiety-like behavior are centrally mediated as overexpression of Glo1 in neurons was sufficient to increase anxiety-like behavior
Studies indicate that the most extensively investigated The most extensively investigated glyoxalase enzymes are glyoxalase I and glyoxalase II (show HAGH Antibodies) (Glo1 and Glo2 (show HAGH Antibodies)).
The GLO1 variations were not the source of association of the BTBD9 (show BTBD9 Antibodies) locus with restless legs syndrome.
Glo1 is involved in the Min-U-Sil (show PMEL Antibodies) 5 crystalline silica-induced BEAS-2B cell mitochondrial apoptotic pathway.
The enzyme encoded by this gene is responsible for the catalysis and formation of S-lactoyl-glutathione from methylglyoxal condensation and reduced glutatione. Glyoxalase I is linked to HLA and is localized to 6p21.3-p21.1, between HLA and the centromere.
, glyoxalase I
, hypothetical protein
, trypanothione-dependent glyoxalase I
, S-D-lactoylglutathione methylglyoxal lyase
, glx I
, glyoxalase 1 complex
, glyoxalase 1 regulatory
, glyoxalase 1 structural
, ketone-aldehyde mutase
, glyoxylase 1
, glyoxalase domain containing 1
, lactoyl glutathione lyase